Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial.
Re-using an older cancer drug after it stops working shows promise with potentially fewer side effects, offering patients another treatment option.
This single-center exploratory RCT compared cetuximab-irinotecan rechallenge versus standard third-line regorafenib in RAS WT mCRC, examining whether anti-EGFR rechallenge can overcome acquired resistance. Results suggest rechallenge is a viable precision approach with potential tolerability advantages, warranting further investigation in larger multicenter trials.
What the study was
- Study design
- Single-center exploratory randomized controlled trial
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- BMC Cancer
Why it surfaced
Randomized trial in mCRC rechallenge strategy; precision oncology context (RAS WT selection); directly relevant to T5 and T6 watchlists; exploratory but provides RCT-level evidence for a growing precision oncology approach.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.